A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Pfizer

Status and phase: Completed; Phase 3

Conditions: Upper Respiratory Tract Infection

Treatments: Drug: Azithromycin SR

Study type: Interventional

Funder types: Industry

Identifiers

NCT00393835

A0661176

Details and patient eligibility

About

To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.

Enrollment: 99 patients

Sex: All

Ages: 16 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were diagnosed Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Exclusion criteria

• Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)